Skip to main content
. 2021 Jul 29;12:675542. doi: 10.3389/fimmu.2021.675542

Figure 3.

Figure 3

Tofacitinib inhibits the activation of CD4+ T cells by increasing TGFβRI expression in vitro. Naïve CD4+ T cells from PBMCs of SLE patients (n = 4) were stimulated with anti-CD3/CD28 beads in the absence or presence of TOF (0.1-10 µM) for 24 h. (A) TGFβRI (TβRI) mRNA level (n = 4) in naïve CD4+ cells was analyzed. (B, D) The percentages of active CD4+ T cells (CD4+CD69+ T cells) (n = 4) were determined. (C, E) The percentages of active CD4+ T cells (CD4+CD25+ T cells) (n = 4) were determined. Purified naïve CD4+ T cells from SLE patients (n = 5) were stimulated with anti-CD3/CD28 beads in the absence or presence of TOF (0.1µM) with or without 10µM TGFβRI inhibitor SB431542. (F) The percentages of active CD4+ T cells (CD4+CD69+ T cells) (n = 5) were determined. (G) The percentages of active CD4+ T cells (CD4+CD25+ T cells) (n = 5) were determined. Error bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001. TOF, tofacitinib; SB, SB431542.